<DOC>
	<DOCNO>NCT00719836</DOCNO>
	<brief_summary>This study consist two phase : first portion study Phase 1 dose escalation study determine maximum tolerate dose dose limit toxicity SB1518 give single agent orally daily subject advance myeloid malignancy ; second portion study Phase 2 study define efficacy safety profile single-agent SB1518 recommend dose subject chronic idiopathic myelofibrosis ( CIMF ) .</brief_summary>
	<brief_title>A Phase 1/2 Study SB1518 Treatment Advanced Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<criteria>Inclusion Criteria During dose escalation phase : subject histologically confirm myeloid malignancy fail standard therapy candidate palliative therapy . This include follow : Subjects Acute Myelogenous Leukemia ( AML ) Subjects Chronic Myelogenous Leukemia ( CML ) accelerate phase Subjects Chronic Myelogenous Leukemia ( CML ) blast crisis Subjects highrisk Myelodysplastic Syndromes ( MDS ) Chronic Myelomonocytic Leukemia ( CMML ) Subjects Advanced Myelofibrosis ( MF ) In Phase 2 , subject CIMF ( well post ET/PV MF ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 All men reproductive potential woman childbearing potential must agree practice effective contraception entire study period one month last study treatment , unless documentation infertility exist . Additionally , woman childbearing potential must negative pregnancy test within 14 day prior first dose study drug Able understand willing sign inform consent form Exclusion Criteria Subjects Chronic Myelogenous Leukemia ( CML ) chronic phase ; Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement judge treat physician . Subjects receive antibiotic infection control may include study ; Concurrent malignancy , except subject early stage squamous cell carcinoma skin , basal cell carcinoma skin , cervical intraepithelial neoplasia eligible study ; Known HIVpositive ( subject increase risk lethal infection treat potentially marrowsuppressive therapy ) ; Known active hepatitis A , B , C ; Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>SB1518</keyword>
	<keyword>Chronic Idiopathic Myelofibrosis</keyword>
	<keyword>JAK2 Inhibitor</keyword>
</DOC>